Alexion Pharmaceuticals, Inc. (ALXN)

[surf1944]

6:36AM Alexion Pharma beats by $0.11, beats on revs; raises FY12 EPS most of range above consensus, raises FY12 revs above consensus (ALXN) 97.55 : Reports Q2 (Jun) earnings of $0.47 per share, excluding non-recurring items, $0.11 better than the Capital IQ Consensus Estimate of $0.36; revenues rose 50.6% year/year to $279.7 mln vs the $262.97 mln consensus. Co raised guidance for FY12, sees EPS of $1.78-1.88 from prior guidance of $1.65-1.75 vs. $1.78 Capital IQ Consensus Estimate; raised FY12 revs to $1.110-1.125 bln from prior guidance of $1.065-1.085 bln vs. $1.09 bln Capital IQ Consensus Estimate. The European Commission has granted orphan designation for eculizumab as a treatment for patients with STEC-HUS, a severe, ultra-rare, and life-threatening inflammatory disorder. Separately, enrollment continues in a Company-sponsored, multi-national, living-donor kidney transplant trial in patients at elevated risk of acute humoral rejection, also known as antibody mediated rejection, and the Company has initiated a deceased-donor kidney transplant study with enrollment expected to begin later this year.